Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial.
Zarbock A, Larsson TE, Noiseux N, Mazer CD, B?hm J, Laflamme M, Matschke K, Burkert J, de Varennes B, Myjavec A, B?ning A, Koyner JL, Engelman D, Reusch M, Thielmann M. Efficacy and safety of therapeutic alpha-1-microglobulin RMC-035 in reducing kidney injury after cardiac surgery: a multicentre, randomised, double-blind, parallel group, phase 2a trial. EClinicalMedicine. 2024 Oct; 76:102830.